Skip to main content
. 2012 Mar 7;6:67–77. doi: 10.4137/BCBCR.S6374

Figure 2.

Figure 2

The Neo-Adjuvant Lapatinib and/or Trastuzumab Treatment Organization (Neo-ALTTO) study is a randomized, multicentre open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer. Her 2 Her 3 Her 4